Researchers using genetic data from over 200,000 men say those predisposed to androgenetic alopecia face added risk. Lead author Lynn Petukhova suggests screening someday.
Recap by typeshit. Full story at Muscle & Fitness.
The REDEFINE 1 data covered 2,309 women, with placebo at 3%. In the REDEFINE 4 head-to-head, tirzepatide matched or slightly beat it.
Superpower says the drug carries radiation straight to cancer cells and cites a phase 3 trial showing a 79% lower risk of progression or death. A 14-part thread.
Australian experts note about half a million people there use GLP-1 drugs for diabetes alone, and lay out what new users should keep in mind about nutrition.
A herpetology-themed clip from PBS points to reptiles as part of the story behind today's GLP-1 medications. Short and light, but a fun bit of history.
A systematic review cited by Dr. Axe found human safety data on BPC-157 comes from just 30 people, a thin base for a widely used peptide.
Le Figaro reports the tablet arrives in early November. Unlike the Wegovy injection, it won't be covered by France's public reimbursement system.
Loading…